Scientific Advisory Panel

Prof Ross McKinnon 250x324

Professor Ross McKinnon BPharm BSc(Hons) PhD


Professor Ross McKinnon is the Director of Flinders Centre for Innovation in Cancer at Flinders University and Associate Dean Research in the School of Medicine at Flinders University. He is also a Vice-President of the International Pharmaceutical Federation (FIP). As an academic pharmacist, Ross has broad research interests in the pharmacology, pharmaceutical biotechnology and molecular oncology areas.

margaret tempero 250x324

Margaret Tempero, M.D.

Dr. Tempero is a Professor of Medicine and Director of the University of California, San Francisco Pancreas Center. Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She has extensive experience in scientific review and administration, training and oversight. Dr. Tempero currently serves as the Editor-in-Chief of the Journal of the National Comprehensive Cancer Network (JNCCN), Chair of the NCCN Pancreas Cancer Guidelines Panel and past President of the American Society of Clinical Oncology (ASCO).

Andrew Lowy 250x324

Andrew M. Lowy, MD

Professor of Surgery. Chief, Division of Surgical Oncology - Moores Cancer Centre, University of California, San Diego

Dr Lowy is a surgical oncologist with a primary interest and expertise in cancers of the pancreas. He is recognized worldwide for his expertise in the surgical treatment of pancreatic cancer and for investigating novel cancer treatments in patients with advanced cancer that has spread to the abdomen. Dr. Lowy serves on the editorial board of the Annals of Surgical Oncology and is the co-chair of the National Cancer Institute’s Pancreatic Cancer Task Force. He serves as the surgical principal investigator in the largest pancreatic cancer clinical trial ever conducted in the United States.

nick pavlakis 250x324

Associate Professor Nick Pavlakis BSc MBBS MMed Clin. Epi. PhD FRACP

A/Prof Nick Pavlakis is Senior Staff Specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Associate Professor in the Faculty of Medicine University of Sydney. As an academic medical oncologist he has published extensively in the area of gastrointestinal cancers and has been author and chapter lead in national clinical practice guidelines in mesothelioma, breast and lung cancers.

He has previously served on the Executive of the Medical Oncology Group of Australia (MOGA), the Private Cancer Physicians Group of Australia (PCPA), the Australian Lung Cancer Trials Group (current Chair of Scientific Advisory Committee) and on national and international cancer advisory boards.

Pete Coffey 250x324

Professor Pete Coffey

Head of Ocular Biology & Therapeutics Institute of Ophthalmology - University College London

Professor Coffey is internationally recognised as the leading expert in human embryonic stem cells and their potential use to cure blindness. He has many years of experience in cellular therapies as applied to retinal transplantation and recently was the principal author and co-author of two landmark papers demonstrating that implanting human cells could prevent visual loss. Coffey has established the London Project to Cure Blindness which aims to deliver a human stem cell therapy for age-related macular degeneration.

John Chen 250x324

Dr John Chen


Dr Chen is a HepatoPancreatoBiliary and Liver Transplant Surgeon at Flinders Medical Centre and Royal Adelaide Hospital. He is also the Director of South Australian Liver Transplant Unit at Flinders Medical Centre.

Dr Chen's research interests include pancreatic, biliary and liver malignacies.

Dr Eileen OReilly

Eileen O’Reilly M.D.

Associate Director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer at Memorial Sloan Kettering Cancer Center
Attending Physician, Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College

Dr O’Reilly is a Medical Oncologist and Researcher who’s research initiatives include the integration of molecular and genetic-based therapies into the treatment of pancreas cancer, developing adjuvant and neoadjuvant therapies, and identifying biomarkers that may be used to select therapy. She is the principal investigator of multiple phase I, II, and III clinical trials in pancreas cancer and has authored and co-authored many articles, editorials, and book chapters.

Within the United States, Dr O’Reilly holds several prominent national positions for Pancreatic Cancer including: Chair of the Alliance GI Committee, Membership of the Gastrointestinal Cancers Steering Committee, and also serves on the Scientific and Medical Advisory Board of the Pancreas Cancer Action Network and the National Pancreas Foundation.